Dong-A Pharm to introduce Qvar under exclusive licensing agreement with 3M

Published: 2003-01-21 06:56:00

Updated: 2003-01-21 06:56:00

Dong-A Pharm said on January 13 that it singed with 3M of the United States an agreement for the exclusive marketing in Korea of Qvar (beclomethasone dipropionate ), a metered dose inhaler (MDI).

Using an innovative DDS technology and novel device mechanism, Qvar have the two types of inhaler...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK